Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,109 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Kidney transplantation Clear all
Completed Not applicable Interventional

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

NCT00005799
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), B-cell Chronic Lymphocytic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Childhood Renal Cell Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, Clear Cell Renal Cell Carcinoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Splenic Marginal Zone Lymphoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, T-cell Large Granular Lymphocyte Leukemia, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Waldenström Macroglobulinemia
Interventions
fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, therapeutic allogeneic lymphocytes, cyclosporine, mycophenolate mofetil, pharmacological study, laboratory biomarker analysis
Drug · Radiation · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
6
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 10, 2026, 4:34 PM EDT
Active, not recruiting No phase listed Observational

Central Blood Pressure and Pulse Wave Velocity in Kidney Transplant Recipients

NCT04212143
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
there is no intervention
Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
3 Years to 21 Years
Enrollment
150 participants
Timeline
2021 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 10, 2026, 4:34 PM EDT
Completed Phase 2 Interventional Results available

Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

NCT03832114
View directory record Official record
Conditions
Glomerulonephritis
Interventions
LNP023
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 10, 2026, 4:34 PM EDT
Completed Not applicable Interventional

Feasibility Study for the Comprehensive Overweight/Obesity Management Pre-Kidney Transplant (COMPKT) Program

NCT06688825
View directory record Official record
Conditions
Kidney Transplant; Complications, Obesity
Interventions
Education regarding Weight loss, Lifestyle tools for weight loss, Blood draw
Behavioral · Biological
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 10, 2026, 4:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Treg Therapy in Subclinical Inflammation in Kidney Transplantation

NCT02711826
View directory record Official record
Conditions
Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant, Living Kidney Donor
Interventions
Polyclonal Regulatory T Cells, Everolimus, Tacrolimus, Mycophenolate mofetil, Mycophenolic acid, Acetaminophen, Diphenhydramine, Biopsy, Kidney, Blood Draw, Leukapheresis, IS regimen conversion
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 10, 2026, 4:34 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection

NCT00089947
View directory record Official record
Conditions
Renal Transplantation, Graft Rejection
Interventions
Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
19
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 10, 2026, 4:34 PM EDT
Active, not recruiting Not applicable Interventional

Promoting Increases in Living Donation Via Tele-navigation (PILOT)

NCT05468463
View directory record Official record
Conditions
Kidney Diseases
Interventions
Living Donor Navigator Program
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 10, 2026, 4:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Donors With Nephrolithiasis at the Time of Transplant Evaluation (DONATE). Long Term Follow-up.

NCT05519150
View directory record Official record
Conditions
Kidney Stones
Interventions
low dose radiation abdomen/pelvis CT scan (stone protocol), Blood draw, 24 hour urine collection
Diagnostic Test · Procedure · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Sep 10, 2026, 4:34 PM EDT
Completed Not applicable Interventional

Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision

NCT05879302
View directory record Official record
Conditions
End Stage Renal Disease, End-Stage Kidney Disease, Kidney Transplantation, Esrd
Interventions
Kidney Offer Shared Decision Making
Behavioral
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 10, 2026, 4:34 PM EDT
Recruiting Phase 2 Interventional

Atacicept in Multiple Glomerular Diseases

NCT06983028
View directory record Official record
Conditions
pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
Interventions
Atacicept
Drug
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 10, 2026, 4:34 PM EDT
Completed Phase 1Phase 2 Interventional

Transplant and Addiction Project (TAP) - 1

NCT00249652
View directory record Official record
Conditions
End Stage Liver Disease, End Stage Renal Disease, Substance-Related Disorders
Interventions
TAP, TAU
Behavioral · Other
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
3
States / cities
New York, New York • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 10, 2026, 4:34 PM EDT
Not listed Phase 4 Interventional

Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)

NCT04849533
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Belatacept, Everolimus, mycophenolate mofetil, corticosteroids, rabbit antithymocyte globulin
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 10, 2026, 4:34 PM EDT
Terminated Not applicable Interventional

Evaluate Tolerability of Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations

NCT01387659
View directory record Official record
Conditions
Diabetes, Immunosuppression
Interventions
Gastric emptying test
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Sep 10, 2026, 4:34 PM EDT
Withdrawn No phase listed Observational

Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus

NCT04216303
View directory record Official record
Conditions
Diabetes, Liver Transplant; Complications, Kidney Transplant Failure
Interventions
hemoglobin A1c
Diagnostic Test
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Sep 10, 2026, 4:34 PM EDT
Active, not recruiting No phase listed Observational

Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection

NCT04727788
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Not listed
Lead sponsor
Verici Dx
Industry
Eligibility
18 Years to 80 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
Chicago, Illinois • Evanston, Illinois • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 10, 2026, 4:34 PM EDT
Completed Phase 4 Interventional Results available

Belatacept Early Steroid Withdrawal Trial

NCT01729494
View directory record Official record
Conditions
Renal Transplantation
Interventions
Alemtuzumab, rabbit antithymocyte globulin, Belatacept, Tacrolimus, Mycophenolate mofetil, early cessation of steroids
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 10, 2026, 4:34 PM EDT
Completed Not applicable Interventional

Discharge to Home and Chronic Illness Care Pilot

NCT02165423
View directory record Official record
Conditions
Solid Organ Transplant
Interventions
myFAMI iPad application
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Sep 10, 2026, 4:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above

NCT05921903
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA Investigational Vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Chicago, Illinois • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 10, 2026, 4:34 PM EDT
Completed No phase listed Observational

Correlation of Donor-specific Anti-endothelial Cells

NCT01545713
View directory record Official record
Conditions
Living-Donor Kidney Transplants
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Sep 10, 2026, 4:34 PM EDT
Terminated Phase 4 Interventional Results available

Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients

NCT00646282
View directory record Official record
Conditions
Hyperparathyroidism, Secondary
Interventions
doxercalciferol
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 10, 2026, 4:34 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Design of a Standardized Patient: Mentoring Program for Kidney Transplant Patients

NCT03490188
View directory record Official record
Conditions
Kidney Transplant; Complications
Interventions
Discharge Mentoring
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Sep 10, 2026, 4:34 PM EDT
Terminated Phase 2 Interventional Results available

Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients

NCT02991768
View directory record Official record
Conditions
Diarrhea
Interventions
Entocort, Placebos
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 10, 2026, 4:34 PM EDT
Terminated Phase 2 Interventional

Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma

NCT00318110
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
NST using MUD for metastatic renal cell carcinoma
Procedure
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Sep 10, 2026, 4:34 PM EDT
Active, not recruiting Phase 1 Interventional

Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

NCT04540380
View directory record Official record
Conditions
Renal Failure
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab, Combined bone marrow and kidney transplant
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 10, 2026, 4:34 PM EDT